Ozempic and Wegovy are the two hottest drugs on the market for diabetes and weight loss management respectively. Embraced from Hollywood to the Hamptons to hospitals, and even a few tech billionaires, Novo Nordisk, the Danish pharmaceutical behind these two drugs, has seen its stock price double over the past year as patient demand continues to grow. On March 29th at 11am ET, join CNBC's Healthy Returns Summit for a discussion with Lars Fruergaard Jørgensen, the CEO behind it all.
Tidak ada komentar:
Posting Komentar